Increased serum 90K and galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas

Seok Jin Kim, Seung Jin Lee, Hwa Jung Sung, In Keun Choi, Chul Won Choi, Byung Soo Kim, Jun Suk Kim, Woosung Yu, Hee Sang Hwang, In Sun Kim

Research output: Contribution to journalArticle

27 Citations (Scopus)


The role of 90K and galectin-3 in cell-to-extracellular matrix adhesion and tumor metastasis has been reported, but little is known about their role in the prognosis and extranodal involvement of diffuse large B-cell lymphomas (DLBCL). Thus, we measured serum 90K concentration by enzyme-linked immunosorbent assay and tissue expression of galectin-3 by immunohistochemistry in newly diagnosed DLBCL patients. The mean serum 90K concentration was higher in DLBCL than in healthy controls (1,408.81 ± 89.45 vs. 980.94 ± 58.69 ng/ml, p = 0.036). High serum 90K (median value ≥1,249.50 ng/ml) and high galectin-3 expression (grade 3 positive staining in >75% of cells) showed a significant association with stage III/IV, ≥2 extranodal involvements and risk of high/high-intermediate international prognostic index (p < 0.05). The complete response (CR) rate (86.9%, 20/23) in the low 90K group was higher than in the high 90K group (56.5%, 13/23). Among 14 patients with high galectin-3 expression, only 6 patients showed CR (42.9%). The time to progression and overall survival were shorter in the group with high 90K and galectin-3 expression (p < 0.05). In conclusion, serum 90K and galectin-3 expression might be useful markers to indicate the extent of lymphoma involvement and prognosis in DLBCL.

Original languageEnglish
Pages (from-to)211-216
Number of pages6
JournalActa Haematologica
Issue number4
Publication statusPublished - 2009 Mar 1



  • 90K
  • Diffuse large B-cell lymphoma
  • Galectin-3
  • Lymphomas

ASJC Scopus subject areas

  • Hematology

Cite this